InventisBio (SH:688382) Zheng Quan Zhi Xing·2025-07-30 00:07Group 1 - Penghua Fund recently conducted research on Yifang Biotechnology, discussing the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - Gexuolei Tablets (brand name Anfangning) received approval from the National Medical Products Administration for market launch in November 2024, targeting adult patients with advanced non-small cell lung cancer (NSCLC) who have undergone at least one systemic treatment and have KRS G12C mutations [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while YF087 and YF550 have made progress in preclinical studies [1] Group 2 - As of now, Penghua Fund has an asset management scale of 943.385 billion yuan, ranking 10th out of 210 [2] - The asset management scale for non-monetary public funds is 492.335 billion yuan, also ranking 10th out of 210 [2] - The fund manages 691 public funds, ranking 8th out of 210, with 83 public fund managers, ranking 11th out of 210 [2] - The best-performing public fund product in the past year is Penghua Carbon Neutrality Theme Mixed A, with a latest net value of 1.57 and a growth of 137.71% over the past year [2]